• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌初始治疗中肿瘤主体的手术切除。

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

作者信息

Griffiths C T

出版信息

Natl Cancer Inst Monogr. 1975 Oct;42:101-4.

PMID:1234624
Abstract

The effect of tumor bulk resection on survival was studied in 102 patients with stages II and III ovarian cancer. A multiple linear regression equation provuded both simultenaous control of multiple confounding variables and an assessment of these variables as independent predictors of survival. The most important factors were the histologic grade of the tumor and the size of the largest residual tumor mass after operation. Survival time was uniformly poor if the diameter of the largest residual tumor mass exceeded 1.5 cm irrespective of total tumor volume (mean=12.7 months, SE=1.6 mo). Survival time was inversely proportional to residual mass size under 1.6 cm, and surgery improved survival relative to reduction in mass size below this limit. Extensive resections of tumor bulk with failure to remove all masses greater than 1.5 cm in diameter did not influence survival. Surgery provides optimum benefit when all gross tumor can be excised safely.

摘要

对102例II期和III期卵巢癌患者研究了肿瘤大块切除对生存的影响。一个多元线性回归方程既可以同时控制多个混杂变量,又可以评估这些变量作为生存的独立预测因素。最重要的因素是肿瘤的组织学分级和术后最大残留肿瘤块的大小。如果最大残留肿瘤块的直径超过1.5厘米,无论肿瘤总体积如何,生存时间均较差(平均=12.7个月,标准误=1.6个月)。在1.6厘米以下,生存时间与残留肿块大小成反比,相对于低于此限度的肿块大小减小,手术可改善生存。对肿瘤大块进行广泛切除但未能切除所有直径大于1.5厘米的肿块并不影响生存。当所有肉眼可见肿瘤能够安全切除时,手术可带来最佳获益。

相似文献

1
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.卵巢癌初始治疗中肿瘤主体的手术切除。
Natl Cancer Inst Monogr. 1975 Oct;42:101-4.
2
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.最大残留病灶直径对初次细胞减灭术后次优残留上皮性卵巢癌患者生存的影响。
Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80. doi: 10.1016/s0002-9378(94)70090-7.
3
Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
Cancer. 1992 Oct 15;70(8):2129-36. doi: 10.1002/1097-0142(19921015)70:8<2129::aid-cncr2820700820>3.0.co;2-u.
4
Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration.上皮性卵巢癌的二次剖腹探查术。与生存时间相关的预后因素。
Cancer. 1988 Jun 15;61(12):2571-7. doi: 10.1002/1097-0142(19880615)61:12<2571::aid-cncr2820611231>3.0.co;2-o.
5
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.一种新的晚期卵巢癌间歇肿瘤减灭术后残留病灶分类方法,可更好地区分肿瘤学结局。
Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10.
6
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.手术细胞减灭术对IV期上皮性卵巢癌生存的影响。
Gynecol Oncol. 1999 Mar;72(3):278-87. doi: 10.1006/gyno.1998.5145.
7
[Surgery in ovarian carcinoma].[卵巢癌手术]
Gan To Kagaku Ryoho. 1995 Aug;22(9):1176-81.
8
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.上皮性卵巢癌国际妇产科联盟(FIGO)分期 IIA-IV 期患者残余肿瘤大小的预后价值:OVCAD 数据分析。
Int J Gynecol Cancer. 2012 Mar;22(3):380-5. doi: 10.1097/IGC.0b013e31823de6ae.
9
[Clinical characteristics and prognosis of epithelial ovarian cancer in young women].[年轻女性上皮性卵巢癌的临床特征与预后]
Ai Zheng. 2008 Sep;27(9):951-5.
10
The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.最佳初次肿瘤细胞减灭术后微小残留Ⅲ期上皮性卵巢癌中肿瘤分级、播散及癌灶范围的影响
Gynecol Oncol. 1994 Oct;55(1):108-10. doi: 10.1006/gyno.1994.1257.

引用本文的文献

1
Isolated Liver Recurrence After Cytoreduction in High-Grade Serous Ovarian Carcinoma: Experience of a Tertiary Center in Turkey.高级别浆液性卵巢癌肿瘤细胞减灭术后孤立性肝转移:土耳其一家三级中心的经验
J Clin Med. 2025 Mar 7;14(6):1791. doi: 10.3390/jcm14061791.
2
Fluorescence-Guided Surgery to Detect Microscopic Disease in Ovarian Cancer: A Systematic Review with Meta-Analysis.荧光引导手术检测卵巢癌微小病灶:一项系统评价与Meta分析
Cancers (Basel). 2025 Jan 26;17(3):410. doi: 10.3390/cancers17030410.
3
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer.
晚期上皮性卵巢癌初始治疗中,术前新辅助化疗与手术加化疗的比较。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub7.
4
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) of Extraperitoneal Abdominal Disease, is it Appropriate?腹膜外腹部疾病的细胞减灭术联合腹腔热灌注化疗(CRS-HIPEC),是否合适?
Ann Surg Oncol. 2025 Apr;32(4):2893-2902. doi: 10.1245/s10434-024-16866-6. Epub 2025 Feb 4.
5
Duodenal obstruction in a 38-year-old: Case report of an unusual ovarian cancer presentation requiring a Whipple procedure.一名38岁患者的十二指肠梗阻:一例罕见的卵巢癌表现病例报告,需行惠普尔手术。
Heliyon. 2024 Aug 19;10(16):e36581. doi: 10.1016/j.heliyon.2024.e36581. eCollection 2024 Aug 30.
6
A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study.术前评分模型评估卵巢癌肿瘤细胞减灭术(BLOODS 评分)中输血风险:纪念斯隆凯特琳癌症中心卵巢癌研究团队。
Int J Gynecol Cancer. 2024 Jul 1;34(7):1051-1059. doi: 10.1136/ijgc-2024-005660.
7
Author's reply to correspondence on "Expanding the Use of HIPEC in Ovarian Cancer at Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis and Perioperative and Oncologic Outcomes" by Mukurdipi Ray et al.作者对Mukurdipi Ray等人关于“在中间性肿瘤细胞减灭术中将腹腔热灌注化疗扩展应用于FIGO IV期卵巢癌及新辅助化疗6周期后的应用:一项前瞻性分析及围手术期和肿瘤学结局”的通信的回复
Ann Surg Oncol. 2024 Aug;31(8):5121. doi: 10.1245/s10434-024-15503-6. Epub 2024 May 30.
8
First external validity study of the Fagotti score in ovarian cancer.卵巢癌中 Fagotti 评分的首次外部有效性研究。
Sci Rep. 2024 May 27;14(1):12133. doi: 10.1038/s41598-024-62568-0.
9
Correspondence on "Expanding the Use of HIPEC in Ovarian Cancer at Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis and Perioperative and Oncologic Outcomes" by Valentina Ghirardi et al.关于瓦伦蒂娜·吉拉尔迪等人所著的《在中间性肿瘤细胞减灭术中将腹腔热灌注化疗(HIPEC)的应用扩展至国际妇产科联盟(FIGO)IV期卵巢癌以及新辅助化疗6周期后:一项前瞻性分析及围手术期和肿瘤学结局》的通信
Ann Surg Oncol. 2024 Jul;31(7):4582-4583. doi: 10.1245/s10434-024-15399-2. Epub 2024 May 4.
10
Survival impact and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer: a systematic review and meta-analysis.晚期卵巢癌胸腹腔减瘤手术的生存影响及安全性:一项系统评价和荟萃分析
Front Oncol. 2024 Jan 18;14:1335883. doi: 10.3389/fonc.2024.1335883. eCollection 2024.